The COVID-CT registry is designed to evaluate whether SARS-CoV-2 infection accelerates the progression of total and noncalcified atherosclerotic plaque volumes compared to uninfected patients.
Observational
Sí
Does COVID-19 infection accelerate progression of coronary atherosclerotic plaque in patients with pre-existing CAD?
The COVID-CT registry is designed to evaluate whether COVID-19 infection accelerates coronary atherosclerotic plaque progression in patients with pre-existing CAD.
BACKGROUND: Infection with the severe acute respiratory syndrome coronavirus-2 (SARSCoV-2), the virus which causes the corona virus disease-2019 (COVID-19) has substantial evidence that patients with pre-existing coronary artery disease (CAD) have an increased risk of serious illness, adverse coronary events, and mortality following infection. The COVID-CT registry will assess whether COVID-19 alters progression of coronary atherosclerotic plaque in patients with previously defined anatomic CAD on coronary computed tomographic angiography (CCTA). Mediators and covariates such as disease severity, inflammation, and neighborhood deprivation will also be assessed. DESIGN: The COVID-CT registry is a multicenter, longitudinal observational registry enrolling patients including patients with pre-pandemic atherosclerosis observed by CCTA from New York City and Long Island to determine the impact of COVID-19 infection. The primary aim is to test the hypothesis that patients with previously defined anatomic CAD by CCTA who are subsequently infected with SARS-CoV-2 have accelerated progression of total and noncalcified atherosclerotic plaque volumes when compared to uninfected patients. We hypothesize that systemic inflammation is a key promoter in the formation and progression of atherosclerotic plaque. Additionally, we will test whether measurement of the perivascular fat attenuation index detects high risk, coronary artery inflammation following COVID infection. SUMMARY: The impact of this first in-kind registry will be foundational for revising standard diagnostic pathways and risk assessment used to guide preventive care for millions of patients with CAD at increased risk from viral infection.
Soroa et al. (Fri,) conducted a observational in Coronary artery disease and COVID-19. SARS-CoV-2 infection vs. Uninfected patients was evaluated on Progression of total and noncalcified atherosclerotic plaque volumes. The COVID-CT registry is designed to evaluate whether SARS-CoV-2 infection accelerates the progression of total and noncalcified atherosclerotic plaque volumes compared to uninfected patients.